Rising Biosciences (Rising Biosciences) Capex-to-Revenue : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Rising Biosciences's Capital Expenditure for the three months ended in . 20 was $0.00 Mil. Its Revenue for the three months ended in . 20 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Rising Biosciences Capex-to-Revenue Historical Data

The historical data trend for Rising Biosciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Capex-to-Revenue Chart

Rising Biosciences Annual Data

Trend

Capex-to-Revenue

Rising Biosciences Quarterly Data

Capex-to-Revenue

Competitive Comparison of Rising Biosciences's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Capex-to-Revenue falls into.

Rising Biosciences Capex-to-Revenue Calculation

Rising Biosciences's Capex-to-Revenue for the fiscal year that ended in . 20 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- ()	/
	=	N/A

Rising Biosciences's Capex-to-Revenue for the quarter that ended in . 20 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- ()	/
	=	N/A

Rising Biosciences (GREY:RBII) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Rising Biosciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Capex-to-Revenue

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.